⚡ Quick Summary
Sibel Health, a patient monitoring company originating from Northwestern University, has successfully completed a $30 million Series C funding round and has received its seventh FDA clearance for its monitoring platform.
💡 Key Highlights
- 🔑 Funding Details: The Series C round was led by the Steele Foundation for Hope, with participation from Dräger, both of whom are existing investors in Sibel Health.
- ⚙️ FDA Clearance: The latest clearance enhances the ANNE One platform, allowing for alarms and alerts along with a robust central monitoring station.
- 📊 Platform Features: The ANNE One platform includes advanced wearable sensors and AI-driven data analytics, enabling wireless monitoring of vital signs for patients aged 12 and older.
👩⚕️ About the ANNE One Platform
- The platform consists of two wearable components: the Anne Limb, which tracks skin and body temperature, and the Anne Chest, which monitors heart rate, respiratory rate, step count, fall count, and skin temperature.
- It is designed for continuous monitoring, addressing the critical need for real-time patient data, especially in non-ICU settings.
📅 Future Plans
- Sibel Health plans to utilize the new funding to accelerate the commercial rollout of the ANNE One platform across hospitals in the U.S. and Europe.
- Dr. Steve Xu, co-founder and CEO, emphasized the importance of continuous monitoring, noting that many patient deaths occur outside of monitored environments.
🚀 Market Developments
- In December, Sibel Health entered a long-term partnership with the Capital Region of Denmark to implement advanced continuous monitoring in hospitals.
- The company has also launched its physiological monitoring platform, Discovery, for clinical trial applications and partnered with Medidata for AI-driven clinical trial solutions.
- In 2022, Sibel raised $33 million in a Series B funding round, further solidifying its position in the health tech market.
